Next Science Limited (ASX:NXS) has received given licensing approval for XPERIENCE, the company’s advanced irrigation product, to be sold in Canada.
The company launched XPERIENCE in the US in April 2021 and applied for licensing in Canada in May 2021.
The Health Canada licensing approval allows Next Science to sell XPERIENCE throughout Canada. With more than a million surgical procedures performed in Canada annually, the company is working on plans to launch XPERIENCE in the Canadian market during H2 2022.
Next Science will build a sales agent distribution network and will commence a major randomised control study which will compare XPERIENCE against current standard of care and the rate of post operative infections.
The principal investigator for the study has been engaged and is based out of the University of Ottawa.
There were over 110,000 hip and knee surgeries completed in Canada in 2020/20212 and more than 50,000 orthopaedic trauma surgeries.
All surgical groups were reduced in number from previous years due to the negative impact of COVID on hospital activity.
We are thrilled to see this licence come through and can now move to both commercial and clinical research activity in Canada. We look forward to the differences we can show in such a well-documented health system,” Managing Director, Judith Mitchell, said.
